Status:
COMPLETED
CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
Lead Sponsor:
EMagnusson
Conditions:
Kidney Transplantation
Kidney Diseases
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The advent of new, potent immunosuppressive (anti-rejection) drugs over the past ten years has substantially reduced the risk of rejection after kidney transplantation, has allowed the development of ...
Detailed Description
RECENT EXPERIENCE AT ST MARY'S: The St Mary's Hospital Renal Unit (now combined with the Hammersmith Hospital Renal Unit at the West London Renal and Transplant Centre) introduced Tacrolimus based im...
Eligibility Criteria
Inclusion
- Kidney transplant recipients under the care of the West London Renal and Transplant Centre
Exclusion
- Patients who are unable to give written informed consent
- Simultaneous kidney/pancreas transplant recipients
- Non-heart beating deceased donor transplant recipients
- Patients who would not be offered Campath-1H induction under our current protocol (patients with previous malignancy or with previous exposure to cytotoxic or antiproliferative agents)
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT00246129
Start Date
October 1 2005
End Date
June 1 2011
Last Update
September 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West London Renal and Transplant Centre, 4th Floor Ham House, Hammersmith Hospital
London, United Kingdom, W12 OHS